other material
confidence high
sentiment positive
materiality 0.55
Vaxart secures $37.7M additional BARDA funding for oral COVID-19 vaccine trial
Vaxart, Inc.
- Modification No. 4 increases allotted trial funding from ~$96.5M to ~$134.2M.
- Additional $37.7M for mRNA comparator acquisition and clinical site readiness.
- Total estimated ceiling raised by ~$4.6M to ~$460.7M.
- Trial compares Vaxart's oral XBB COVID-19 vaccine to an FDA-approved mRNA vaccine.